A team of biomedical engineers, venture capitalists and device businesspeople are launching a new incubator for med tech startups in Silicon Valley.
Array BioPharma has formed a drug discovery pact with Biogen Idec to develop inhibitors targeting a novel kinase for the treatment of autoimmune disorders.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.
Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
GlaxoSmithKline's oncology division is retooling and adding a new focus on the emerging field of T-cell engineering in immuno-oncology. And in the process the pharma giant is sending a clear message that it still sees a bright future for itself in cancer drug research.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
As rates of drug-resistant tuberculosis rise across the globe, GlaxoSmithKline is partnering with Switzerland's BioVersys and France's University of Lille to develop a preclinical candidate against the airborne disease.
Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts.
The U.K.'s PolyTherics, which just this week merged with Antitope to pool their resources in R&D, announced that it would also collaborate with Canadian company Alpha Cancer Technologies, which has a drug delivery platform called alpha fetoprotein designed to enhance chemotherapy.